sanjivani-paranteralSanjivani Paranteral Ltd.

₹219.5+2.16%

Market Cap

₹0.00 Cr

Stock P/E

0.00

ROCE

0.00%

ROE

0.00%

Book Value

₹0.00

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Strong Q3 performance with double-digit growth and favorable export mix.
•
Q3 revenue and margins indicate improving profitability.

NEGATIVES

•
Gross margin contraction in Q3 due to product mix and lower-margin tenders in Latin America.
•
One-off higher costs from compliance inspections impacting near-term profitability.

Peers Summary

Sector Leader

Sanjivani Paranteral Ltd. is underperforming relative to its peers across key financial metrics, revealing a lack of growth and profitability. The peer group shows strong players like Sun Pharmaceuticals and Mankind Pharma, which highlight a stark contrast in financial health and growth prospects. While Sanjivani has a low debt ratio, it also exhibits no revenue or EPS growth, putting it at a disadvantage.

Key Points

• Sanjivani has 0% revenue growth and no profitability metrics reported.
• Sun Pharmaceutical and Mankind Pharma are leading in revenue growth and profitability.
• Divi's Laboratories shows high PE but weak revenue growth, indicating possible overvaluation.

Top Performers

Sun Pharmaceutical Industries Ltd.

Highest revenue growth (YoY 8.42%) and strong profitability metrics (ROE 16.13%).

Mankind Pharma Ltd.

Best growth trajectory with outstanding 3-Year revenue growth (155.25%) and solid profitability (ROE 23.15%).

Dr. Reddy's Laboratories Ltd.

Strong profitability indicators (ROE 21.76%) and attractive valuation metrics (PE 15.50).

Explore

Watchlists

Command Palette